Announcements
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
- uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
More ▼
Key statistics
On Monday, Uniqure NV (QUREN:MEX) closed at 84.39, -28.86% above its 52-week low of 118.63, set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 78.82 |
Average volume | 0.00 |
---|---|
Shares outstanding | 48.55m |
Free float | 46.47m |
P/E (TTM) | -- |
Market cap | 240.32m USD |
EPS (TTM) | -6.20 USD |
Data delayed at least 20 minutes, as of Nov 27 2023 11:30 GMT.
More ▼